For decades, scientists have been trying to produce safe, cost effective nanomaterials. Now,...
- Drugs from corn? Harvesting Mirexus’ phytoglycogen nano-particle
- James MacKenzie Q&A: How late-stage packaging customisation is shaking up the pharmaceutical supply chain
- Where is the UK’s supply of Migraleve?
- UK prioritises transport of medical products in no-deal Brexit scenario
- FDA announces another carcinogenic impurity in ARB blood pressure drugs
Drugs from corn? Harvesting Mirexus’ phytoglycogen nano-particle
For decades, scientists have been trying to produce safe, cost effective nanomaterials. Now, Canadian company Mirexus may have found a way to do this, using technology to extract a non-toxic, nano-material from corn. Sally Turner spoke to CEO of Mirexus to find out more.
James MacKenzie Q&A: How late-stage packaging customisation is shaking up the pharmaceutical supply chain
Tablets in blisters may seem like a simple, everyday item, but in reality the manufacturing process is highly sophisticated. The trend toward smaller batch sizes and higher numbers of packaging variants is driving many manufacturers to turn to ‘postponement’ to improve the efficiency of their supply chains.
European pharma body warns of Brexit drug supply risk to EU
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has raised concerns regarding the post-Brexit supply of medicines from the UK to the European Union (EU).
Louisiana’s subscription model for hepatitis C drugs attracts bids from big players
The proposed procurement model would provide unlimited access to hepatitis C drugs for a flat fee paid to the winning manufacturer.
Where is the UK’s supply of Migraleve?
Migraleve Pink pain relief tablets have been missing from pharmacy shelves in the UK, to the concern of migraine sufferers, some of whom describe it as “the only thing that works”. What’s the cause of Migraleve Pink’s mysterious disappearance, and could manufacturer Johnson & Johnson have been clearer to customers about the supply disruption?
UK prioritises transport of medical products in no-deal Brexit scenario
Despite continued attempts to reach a deal acceptable to Parliament in order for the UK to leave the European Union (EU) with a deal on 29 March, various UK Government departments have listed critical goods that will be considered for transport through extra freight capacity in case of a no-deal situation.
Maharshi: High-performance packaging and printing machines
Indian company Maharshi provides high-performance machines for labelling, printing, visual inspection and leak testing for a number of industries. In North America, its exclusive distributor is Daiichi Jitsugyo (DJA). We talk to DJA vice-president Rusty Nelson about these specialist machines and what sets his company apart from others in the field.
Brexit risks disruption of UK medicines destined for EU
Nineteen centrally authorised human medicinal products were considered “at risk” for supply problems to the EU.
FDA announces another carcinogenic impurity in ARB blood pressure drugs
The US Food and Drug Administration (FDA) has revealed that a third impurity has been found in generic angiotensin II receptor blocker (ARB) drugs indicated for blood pressure and heart failure.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.